Program
nivegacetor
A development code. Also written as “RO7269162” and “[ 14C]-labeled RO7269162”.
Its studies are mostly in Alzheimer Disease, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 21 open or running | phase 2since May 3, 2024 | May 3, 2024 | Nov 19, 2026phase 2 · NCT06402838 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6289 nivegacetor
, phase 2, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 3, 2024First study: phase 2 study in Alzheimer DiseaseFirst studyNCT06402838 · 256 enrolled · Chile, Denmark, France and more
- Dec 10, 2024Phase 1 study in Healthy VolunteersNCT06733298 · 8 enrolled · Netherlands
Ahead
- Nov 19, 2026Primary completion: phase 2 study in Alzheimer DiseaseNCT06402838
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06733298Healthy Volunteers · Netherlands | 1 | Completed | Jan 29, 2025 | 8 |
| NCT06402838Alzheimer Disease · Chile, Denmark, France and more | 2 | Active, not recruiting | Nov 19, 2026 | 256 |
How it is read
Names in the registry
- “RO7269162”, 1 entry
- “[ 14C]-labeled RO7269162”, 1 entry
Codes read as this program: RO7269162.
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.